Letter to the Editor: Experience with subcutaneous desmopressin in patients with von Willebrand disease (VWD) and qualitative platelet function disorders-Reference-Cited by-同舟云学术

Letter to the Editor: Experience with subcutaneous desmopressin in patients with von Willebrand disease (VWD) and qualitative platelet function disorders

Published:2023-01-17 Issue:2 Volume:29 Page:676-680
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Saey Stephanie¹^ORCID,Sharathkumar Anjali¹²,Watkinson Karla²,Krantz Michelle²,Currie Allison²,Perepu Usha²,Shinkle Marie²³

Affiliation:

1. Carver College of Medicine University of Iowa Iowa City Iowa USA

2. University of Iowa Stead Family Children's Hospital Department of Pediatric Hematology and Oncology Iowa City Iowa USA

3. Department of Pharmaceutical Care University of Iowa Hospitals and Clinics Iowa City Iowa USA

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14744

Reference10 articles.

1. Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First 20 Years

2. Ferring Pharmaceuticals.2020.Ferring US issues voluntary nationwide recall of DDAVP® Nasal Spray 10 mcg/0.1 mL Desmopressin Acetate Nasal Spray 10 mcg/0.1 mL STIMATE® Nasal Spray 1.5 mg/mL due to superpotency.https://www.fda.gov/safety/recalls‐market‐withdrawals‐safety‐alerts/ferring‐us‐issues‐voluntary‐nationwide‐recall‐ddavpr‐nasal‐spray‐10‐mcg01ml‐desmopressin‐acetate#recall‐announcement

3. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease

4. Prospective Multicenter Study on Subcutaneous Concentrated Desmopressin for Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A

5. Evaluation of the effectiveness of DDAVP in surgery and bleeding episodes in hemophilia and von Willebrand's disease: a study of 43 patients;Mariani G;Clin Lab Haemotol,1984